Xponance Inc. Lowers Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Xponance Inc. trimmed its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.2% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 15,501 shares of the biopharmaceutical company’s stock after selling 28 shares during the period. Xponance Inc.’s holdings in Regeneron Pharmaceuticals were worth $16,292,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in REGN. Brown Lisle Cummings Inc. lifted its position in Regeneron Pharmaceuticals by 18.2% during the second quarter. Brown Lisle Cummings Inc. now owns 65 shares of the biopharmaceutical company’s stock valued at $68,000 after purchasing an additional 10 shares during the period. Sachetta LLC lifted its position in Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 10 shares during the period. Team Hewins LLC lifted its position in Regeneron Pharmaceuticals by 2.5% during the first quarter. Team Hewins LLC now owns 451 shares of the biopharmaceutical company’s stock valued at $434,000 after purchasing an additional 11 shares during the period. Angeles Wealth Management LLC lifted its position in Regeneron Pharmaceuticals by 3.5% during the first quarter. Angeles Wealth Management LLC now owns 325 shares of the biopharmaceutical company’s stock valued at $313,000 after purchasing an additional 11 shares during the period. Finally, TrinityPoint Wealth LLC lifted its position in Regeneron Pharmaceuticals by 4.8% during the fourth quarter. TrinityPoint Wealth LLC now owns 262 shares of the biopharmaceutical company’s stock valued at $230,000 after purchasing an additional 12 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Marion Mccourt sold 1,137 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $1,047.11, for a total transaction of $1,190,564.07. Following the sale, the executive vice president now directly owns 12,931 shares in the company, valued at $13,540,179.41. The disclosure for this sale can be found here. In the last three months, insiders have sold 9,270 shares of company stock worth $10,695,833. 7.48% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on REGN shares. Piper Sandler boosted their target price on shares of Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the company an “overweight” rating in a research report on Friday, August 23rd. TD Cowen boosted their target price on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a research report on Tuesday, July 23rd. Truist Financial reaffirmed a “buy” rating and issued a $1,200.00 price objective (up previously from $1,135.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 2nd. Barclays lifted their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $1,152.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, June 27th. One analyst has rated the stock with a sell rating, two have given a hold rating, sixteen have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $1,111.30.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $1,145.03 on Monday. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. The firm has a market capitalization of $126.17 billion, a price-to-earnings ratio of 33.83, a PEG ratio of 3.93 and a beta of 0.12. The company’s 50-day moving average is $1,131.75 and its two-hundred day moving average is $1,032.63. Regeneron Pharmaceuticals, Inc. has a 1-year low of $769.19 and a 1-year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The firm had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. During the same period in the prior year, the business posted $8.79 EPS. The business’s revenue for the quarter was up 12.3% compared to the same quarter last year. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.